Researchers have identified distinct genetic changes tied to the severity of idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Data showed that the expression (activity) of the ABCA3 gene was lower in IPAH patients, while that of the SMAD9 gene was increased in CTEPH, particularly…

The advocacy organization Phaware has launched a new mobile app to help people living with pulmonary hypertension (PH) better manage their condition. Called Heart Works – phaware, the app is available on iPhone, Apple Watch, and Android devices — launching just in time for…

A new sequential strategy successfully treats people with severe chronic thromboembolic pulmonary hypertension (CTEPH), significantly reducing high blood pressure and improving heart function, a study finds. The three-step regimen — medication, balloon pulmonary angioplasty (BPA), and pulmonary endarterectomy (PEA) surgery — is designed for people facing unacceptably high surgical…

Pulmonary endarterectomy (PEA), a surgery to remove blood clots in individuals with chronic thromboembolic pulmonary hypertension (CTEPH), may be more effective in improving pulmonary circulation and heart function than balloon pulmonary angioplasty (BPA), according to a recent study. After treatment, a higher proportion of patients in the BPA group…

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that Pulmovant is developing to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The MHLW gives this designation to experimental medicines intended to treat conditions affecting fewer than…

Insulin resistance or IR — a reduced response of body tissues to insulin, a hormone that regulates blood sugar levels — was found to correlate with disease severity in people with chronic thromboembolic pulmonary hypertension (CTEPH), according to a new study from researchers in China. Further, the team determined that…

Anoikis, a form of programmed cell death, is involved in the development of chronic thromboembolic pulmonary hypertension (CTEPH), according to a genetic analysis study. Researchers identified two anoikis-related genes associated with CTEPH — PLAUR and HMOX1 — which may serve as diagnostic biomarkers or as…

Treatments that target the prostacyclin pathway hold promise as chronic thromboembolic pulmonary hypertension (CTEPH) treatment for patients who aren’t eligible for surgery, but more data is needed to verify the effectiveness of these medications in this type of pulmonary hypertension, according to the authors of a meta-analysis of…

Abnormalities in blood levels of various microRNAs (miRNAs) — small RNA molecules that regulate other genes in protein production — may contribute to the development and progression of chronic thromboembolic pulmonary…

The Pulmonary Hypertension Association (PHA) is fundraising and advocating with a campaign called “Let Your Light Shine” this November for this year’s pulmonary hypertension (PH) awareness month. “The efforts of PHA and the PH community are making a tremendous impact on the lives of those affected by PH,”…

Long-term oxygen improves exercise capacity in people with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), a study suggests. Twelve weeks of supplemental oxygen led to a significant and clinically relevant improvements in exercise capacity, as assessed with the six-minute walking distance test (6MWD), by 42…

Treatment with Adempas (riociguat) is generally safe and effective for people with pulmonary arterial hypertension (PAH) and coexisting cardiometabolic conditions, or those that affect the heart and metabolism, according to a pooled analysis of clinical trials. “Efficacy and risk assessment results suggest that [Adempas] can be beneficial for…